Skip to main content
Account

Table 5 Distribution of patient response to treatment, in terms of reduction in number of days and hours with headache at each study time (i.e., T6, T12, and T18) with respect to baseline visit (47 patients)

From: Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting

  

Follow-up time

p values from HGLM and pairwise comparisons

Outcome

Responder groups

T6

N (%)

T12

N (%)

T18

N (%)

Test for overall difference

T12–T6

T18–T6

T18–T12

Test for trend

Monthly days of headache

Non-responders: reduction <30%

9 (19.1)

4 (8.5)

2 (4.3)

0.078

0.195

0.114

0.344

0.025

Partial responders:

reduction ≥30–<50%

7 (15.0)

5 (10.6)

4 (8.5)

0.570

0.655

0.655

0.655

0.294

Responders:

reduction ≥50–≤75%

12 (25.5)

22 (46.8)

14 (29.8)

0.024

0.047

0.638

0.107

0.667

High responders: reduction >75%

19 (40.4)

16 (34.1)

27 (57.4)

0.012

0.389

0.140

0.009

0.069

Monthly hours of headache

Non-responders

reduction <30%

7 (14.9)

0 (0.0)

0 (0.0)

<0.001

0.006

0.006

1.000

0.074

Partial-responders:

Reduction ≥30–<50%

2 (4.3)

2 (4.3)

0 (0.0)

1.000

1.000

1.000

1.000

0.215

Responders:

Reduction ≥50–≤75%

13 (27.6)

9 (19.1)

5 (10.6)

0.122

0.266

0.121

0.266

0.038

High responders: reduction >75%

25 (53.2)

36 (76.6)

42 (89.4)

<0.001

0.009

<0.001

0.051

<0.001